First Time Generics Approved In 1999
Executive Summary
1See related information
You may also be interested in...
FDA 1999 stats
CDER received 140 NDAs during 1999. CBER reports 39 new product license applications were submitted in 1999, ten more than in 1998. CBER's approvals for 1999 included four new therapeutic BLA approvals, one NDA for a biologic and one BLA for a significant new indication. (1"The Pink Sheet" Jan. 17, p. 16) omitted BioTime's Hextend for hypovolemia during surgery and counted a different number of new therapeutic BLA approvals. The average time for approval of the five new biologics was 17.1 months. The number of first time generics approved in 1999 was 43 (2"The Pink Sheet" Jan 17, p. 14)
Japan Grants Global-First Approval To Zolbetuximab, 15 Other New Drugs
Astellas's first-in class CLDN18.2-targeting antibody receives its first approval worldwide, while crovalimab and a number of drugs for rare diseases also receive nods from regulators and are now awaiting reimbursement price-listing.